{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:21Z","timestamp":1740107421397,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00280-021-04271-9","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T19:04:42Z","timestamp":1617822282000},"page":"99-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent\/refractory solid tumors"],"prefix":"10.1007","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1488-1326","authenticated-orcid":false,"given":"Chika","family":"Nitani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehisa","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukiko","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"4271_CR1","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","volume":"341","author":"KK Matthay","year":"1999","unstructured":"Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children\u2019s Cancer Group. N Engl J Med 341:1165\u20131173. https:\/\/doi.org\/10.1056\/NEJM199910143411601","journal-title":"N Engl J Med"},{"key":"4271_CR2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","volume":"27","author":"KK Matthay","year":"2009","unstructured":"Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children\u2019s oncology group study. J Clin Oncol 27:1007\u20131013. https:\/\/doi.org\/10.1200\/JCO.2007.13.8925","journal-title":"J Clin Oncol"},{"key":"4271_CR3","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362:2202\u20132211. https:\/\/doi.org\/10.1056\/NEJMra0804577","journal-title":"N Engl J Med"},{"key":"4271_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s10147-018-1281-8","volume":"23","author":"Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A, Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)","year":"2018","unstructured":"Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A, Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG) (2018) Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Int J Clin Oncol 23:965\u2013973. https:\/\/doi.org\/10.1007\/s10147-018-1281-8","journal-title":"Int J Clin Oncol"},{"key":"4271_CR5","first-page":"393","volume":"26","author":"H Shiohira","year":"2010","unstructured":"Shiohira H, Kitaoka A, Shirasawa H, Enjoji M, Nakashima M (2010) Am 80 induces neuronal differentiation in a human neuroblastoma NH-12 cell line. Int J Mol Med 26:393\u2013399","journal-title":"Int J Mol Med"},{"key":"4271_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2220\/biomedres.33.291","volume":"33","author":"H Shiohira","year":"2012","unstructured":"Shiohira H, Kitaoka A, Enjoji M, Uno T, Nakashima M (2012) Am 80 induces neuronal differentiation via increased tropomyosin-related kinase B expression in a human neuroblastoma SH-SY5Y cell line. Biomed Res (Tokyo Japan) 33:291\u2013297. https:\/\/doi.org\/10.2220\/biomedres.33.291","journal-title":"Biomed Res (Tokyo Japan)"},{"key":"4271_CR7","first-page":"755","volume":"4","author":"RK Srivastava","year":"1998","unstructured":"Srivastava RK, Srivastava AR, Cho-Chung YS (1998) Synergistic effects of 8-chlorocyclic-AMP and retinoic acid on induction of apoptosis in Ewing\u2019s sarcoma CHP-100 cells. Clin Cancer Res 4:755\u2013761","journal-title":"Clin Cancer Res"},{"key":"4271_CR8","first-page":"143","volume":"66","author":"R Noguera","year":"1992","unstructured":"Noguera R, Triche TJ, Navarro S, Tsokos M, Llombart-Bosch A (1992) Dynamic model of differentiation in Ewing\u2019s sarcoma cells. Comparative analysis of morphologic, immunocytochemical, and oncogene expression parameters. Lab Investig J Tech Methods Pathol 66:143\u2013151","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"4271_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/pbc.20650","volume":"47","author":"JW Barlow","year":"2006","unstructured":"Barlow JW, Wiley JC, Mous M, Narendran A, Gee MF, Goldberg M, Sexsmith E, Malkin D (2006) Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatr Blood Cancer 47:773\u2013784. https:\/\/doi.org\/10.1002\/pbc.20650","journal-title":"Pediatr Blood Cancer"},{"key":"4271_CR10","first-page":"5264","volume":"48","author":"HE Gabbert","year":"1988","unstructured":"Gabbert HE, Gerharz CD, Biesalski HK, Engers R, Luley C (1988) Terminal differentiation and growth inhibition of a rat rhabdomyosarcoma cell line (BA-HAN-1C) in vitro after exposure to retinoic acid. Cancer Res 48:5264\u20135269","journal-title":"Cancer Res"},{"key":"4271_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/ijc.29886","volume":"58","author":"A Al-Tahan","year":"2012","unstructured":"Al-Tahan A, Sarkis O, Harajly M, Baghdadi OK, Zibara K, Boulos F, Dighe D, Kregel S, Bazarbachi A, El-Sabban M, Skapek SX (2012) Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma. Pediatr Blood Cancer 58:877\u2013884. https:\/\/doi.org\/10.1002\/ijc.29886","journal-title":"Pediatr Blood Cancer"},{"key":"4271_CR12","first-page":"4771","volume":"42","author":"R Thein","year":"1982","unstructured":"Thein R, Lotan R (1982) Sensitivity of cultured human osteosarcoma and chondrosarcoma cells to retinoic acid. Cancer Res 42:4771\u20134775","journal-title":"Cancer Res"},{"key":"4271_CR13","first-page":"153","volume":"41","author":"QJ Yang","year":"2012","unstructured":"Yang QJ, Zhou LY, Mu YQ, Zhou QX, Luo JY, Cheng L, Deng ZL, He TC, Haydon RC, He BC (2012) All-trans retinoic acid inhibits tumor growth of human osteosarcoma by activating Smad signaling-induced osteogenic differentiation. Int J Oncol 41:153\u2013160","journal-title":"Int J Oncol"},{"key":"4271_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/030089169107700505","volume":"77","author":"M Adwankar","year":"1991","unstructured":"Adwankar M, Banerji A, Ghosh S (1991) Differential response of retinoic acid pretreated human synovial sarcoma cell line to anticancer drugs. Tumori 77:391\u2013394. https:\/\/doi.org\/10.1177\/030089169107700505","journal-title":"Tumori"},{"key":"4271_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1475-2867-11-34","volume":"11","author":"ME Smith","year":"2011","unstructured":"Smith ME, Das BC, Kalpana GV (2011) In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines. Cancer Cell Int 11:34. https:\/\/doi.org\/10.1186\/1475-2867-11-34","journal-title":"Cancer Cell Int"},{"key":"4271_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1476-4598-10-136","volume":"10","author":"J Wegert","year":"2011","unstructured":"Wegert J, Bausenwein S, Kneitz S, Roth S, Graf N, Geissinger E, Gessler M (2011) Retinoic acid pathway activity in Wilms tumors and characterization of biological responses in vitro. Mol Cancer 10:136. https:\/\/doi.org\/10.1186\/1476-4598-10-136","journal-title":"Mol Cancer"},{"key":"4271_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11060-007-9380-9","volume":"84","author":"Q Chang","year":"2007","unstructured":"Chang Q, Chen Z, You J, McNutt MA, Zhang T, Han Z, Zhang X, Gong E, Gu J (2007) All-trans-retinoic acid induces cell growth arrest in a human medulloblastoma cell line. J Neurooncol 84:263\u2013267. https:\/\/doi.org\/10.1007\/s11060-007-9380-9","journal-title":"J Neurooncol"},{"key":"4271_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1620\/tjem.221.257","volume":"221","author":"M Yokosawa","year":"2010","unstructured":"Yokosawa M, Sonoda Y, Sugiyama S, Saito R, Yamashita Y, Nishihara M, Satoh T, Kumabe T, Yokoyama M, Tominaga T (2010) Convection-enhanced delivery of a synthetic retinoid Am 80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts. Tohoku J Exp Med 221:257\u2013264. https:\/\/doi.org\/10.1620\/tjem.221.257","journal-title":"Tohoku J Exp Med"},{"key":"4271_CR19","first-page":"220","volume":"68","author":"I Damjanov","year":"1993","unstructured":"Damjanov I, Horvat B, Gibas Z (1993) Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab Investig J Tech Methods Pathol 68:220\u2013232","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"4271_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s002800050535","volume":"39","author":"AA Khan","year":"1996","unstructured":"Khan AA, Villablanca JG, Reynolds CP, Avramis VI (1996) Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol 39:34\u201341. https:\/\/doi.org\/10.1007\/s002800050535","journal-title":"Cancer Chemother Pharmacol"},{"key":"4271_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1158\/1078-0432.CCR-12-2225","volume":"19","author":"GJ Veal","year":"2013","unstructured":"Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson AD, Boddy AV (2013) Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clin Cancer Res 19:469\u2013479. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2225","journal-title":"Clin Cancer Res"},{"key":"4271_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJM198510173131604","volume":"313","author":"S Bershad","year":"1985","unstructured":"Bershad S, Rubinstein A, Paterniti JR, Le NA, Poliak SC, Heller B, Ginsberg HN, Fleischmajer R, Brown WV (1985) Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 313:981\u2013985. https:\/\/doi.org\/10.1056\/NEJM198510173131604","journal-title":"N Engl J Med"},{"key":"4271_CR23","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/jth.13861","volume":"15","author":"H Schwertz","year":"2017","unstructured":"Schwertz H, Rowley JW, Zimmerman GA, Weyrich AS, Rondina MT (2017) Retinoic acid receptor-alpha regulates synthetic events in human platelets. J Thromb Haemost 15:2408\u20132418. https:\/\/doi.org\/10.1111\/jth.13861","journal-title":"J Thromb Haemost"},{"key":"4271_CR24","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/0008-5472.828.65.3","volume":"65","author":"M Abe","year":"2005","unstructured":"Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, Takato T, Nakagawara A, Ushijima T (2005) CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 65:828\u2013834","journal-title":"Cancer Res"},{"key":"4271_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.canlet.2006.05.001","volume":"247","author":"M Abe","year":"2007","unstructured":"Abe M, Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T (2007) Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett 247:253\u2013258. https:\/\/doi.org\/10.1016\/j.canlet.2006.05.001","journal-title":"Cancer Lett"},{"key":"4271_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000139124","volume":"74","author":"M Abe","year":"2008","unstructured":"Abe M, Watanabe N, McDonell N, Takato T, Ohira M, Nakagawara A, Ushijima T (2008) Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology 74:50\u201360. https:\/\/doi.org\/10.1159\/000139124","journal-title":"Oncology"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04271-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04271-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:15:14Z","timestamp":1671819314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04271-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["4271"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04271-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TU has received a research grant from OHARA Pharmaceutical Co.,Ltd. All other authors report no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in compliance with the Institutional Review Board regulations of each site and in accordance with the ethical principles proposed in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from the parents of the patient in this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}